| |
Population pharmacokinetic model to analyze nevirapine
multiple-peaks profile after a single oral dose.
Ibarra M, Vázquez M, Fagiolino P.
J Pharmacokinet Pharmacodyn.
2014 Jul 27.
Abstract
Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in
Hypersensitive and Tolerant HIV-Infected Patients from Malawi.
Dickinson L, Chaponda M, Carr DF, et al
Antimicrob Agents Chemother.
2013 Nov 11.
Abstract
Effect of 7 days of phenytoin on the pharmacokinetics of and the
development of resistance to single-dose nevirapine for perinatal HIV
prevention: a randomized pilot trial.
Fillekes Q, Muro EP, Chunda C, et al
J Antimicrob Chemother.
2013 Jul 17.
Abstract
Pharmacokinetics of phase I nevirapine metabolites following a single dose and
at steady state.
Fan-Havard P, Liu Z, Chou M, et al
Antimicrob Agents Chemother.
2013 Mar 4
Abstract |
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in
Relation to
Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals.
Heil SG, van der Ende ME, Schenk PW, et
al
Ther Drug Monit. 2012 Feb 17.
Abstract |
Integration of data from multiple sources for simultaneous modelling analysis:
experience from nevirapine population pharmacokinetics.
Svensson E, van der
Walt JS, Barnes KI,
et al
Br J Clin Pharmacol.
2012 Feb 2.
Abstract |
Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among
HIV-infected Sub-Saharan
African Women.
Dong BJ, Zheng Y, Hughes MD, et al
AIDS. 2012 Feb 1
Abstract |
Population Pharmacokinetics of Nevirapine in HIV-1 infected Pregnant
Women and their neonates (ANRS 12109).
Benaboud S, Ekouévi DK, Urien S, et al
Antimicrob Agents Chemother.
2010 Oct 18
Abstract |
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected
Cambodian patients (ANRS12154).
Chou M, Bertrand J, Segeral O,
Verstuyft C, et al
Antimicrob Agents Chemother.
2010 Aug 9
Abstract |
Pharmacokinetic Assessment of Nevirapine and Metabolites in HIV-1 Patients with
Hepatic Fibrosis.
Cammett AM, Macgregor TR, Wruck JM,
et al
Antimicrob Agents Chemother. 2009 Jul
20.
Abstract |
Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
Vogel M, Bertram N, Wasmuth JC, et al
J Antimicrob Chemother.
2009 Mar 6.
Abstract
|
Exposure of normal and transformed cells to nevirapine, a reverse
transcriptase
inhibitor,
reduces cell growth and promotes differentiation.
Mangiacasale R, Pittoggi C, Sciamanna I, et al.
Oncogene 2003 May 8;22(18):2750-61
Abstract
Population pharmacokinetics of nevirapine in an unselected cohort of
HIV-1-infected
individuals.
De Maat MM, Huitema AD, Mulder JW, et al.
Br J Clin Pharmacol
2002 Oct;54(4):378-85
Abstract
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected
individuals.
De Maat MM, Huitema AD,Mulder JW, et al.
Br J Clin Pharmacol 2002 May;53(5):552P
Abstract
Pharmacokinetic profiles of nevirapine and indinavir in various fractions
of seminal
plasma.
v an
Praag RM, Repping S, de Vries JW, et al.
Antimicrob Agents Chemother
2001Oct;45(10):2902-2907
Abstract
FULL-TEXT ARTICLE
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in
human
immunodeficiency virus-infected patients. The National Institute of
Allergy and
Infectious
Diseases AIDS Clinical Trials
Group Protocol 241
Investigators.
Zhou XJ, Sheiner LB, D'Aquila RT, et al
Antimicrob Agents Chemother
1999
Paper
|
|
| |
Compensatory Role of Double Mutation N348I/M184V on Nevirapine Binding
Landscape: Insight from Molecular Dynamics Simulation.
Karubiu W, Bhakat S, Soliman ME.
Protein J. 2014 Aug 9.
Abstract
Effect of 7 days of phenytoin on the pharmacokinetics of and the
development of resistance to single-dose nevirapine for perinatal HIV
prevention: a randomized pilot trial.
Fillekes Q, Muro EP,
Chunda C, et al
J Antimicrob Chemother.
2013 Jul 17.
Abstract
FULL-TEXT ARTICLE
Identification
of Drug Resistant Mutations in HIV-1 CRF07_BC Variants Selected by Nevirapine In
Vitro.
Wu H, Zhang HJ, Zhang XM,
et al
PLoS One. 2012;7(9):e44333.
Paper
FULL-TEXT ARTICLE
Panel
of prototypical recombinant infectious molecular clones resistant to nevirapine,
efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL,
et al
Antimicrob Agents Chemother.
2012 Aug;56(8):4522-4
Paper |
FULL-TEXT
ARTICLE
Impact
of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic
Resistance to NVP,
Jiao L, Li H, Li L, et al
AIDS Research and Treatment Vol 2012 , Art ID
637263
Paper
ULL-TEXT ARTICLE|
Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected
Patients Failing First-Line
Antiretroviral Treatment:
A Bayesian Analysis
Ngo-Giang-Huong N, Jourdain G, Amzal
B, et al
PLoS ONE 6(11):
e27427
Paper |
A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers
Increased Risk of
Virological Failure to
Nevirapine Therapy.
Paredes R, Puertas MC, Bannister W,
et al
J Infect Dis. 2011
Sep;204(5):741-752.
Abstract
Analysis of nevirapine resistance in HIV-infected infants who received extended
nevirapine or
nevirapine/zidovudine prophylaxis.
Fogel J, Hoover DR, Sun J,
et al
AIDS. 2011 Apr 24;25(7):911-917.
Abstract
Estimating Frequencies of Minority Nevirapine Resistant Strains in Chronically
HIV-1
Infected Individuals Naive to Nevirapine in Using Stochastic Simulations and a
Mathematical Model
Gadhamsetty S, Dixit NM
J Virol.
2010 Jul 28.
Abstract |
Ultrasensitive Detection of Minor Drug-Resistant Variants for HIV After
Nevirapine Exposure
Using Allele-Specific PCR: Clinical Significance.
Rowley CF, Boutwell CL,
Lee EJ,
et al
AIDS Res Hum Retroviruses.
2010 Mar;26(3):293-300
Abstract |
Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency
Virus
Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but
not to Etravirine.
Gatanaga H, Ode H, Hachiya A, et al
Antimicrob Agents Chemother.
2010 Feb 1
Abstract |
|
|
|
|
| |
FULL-TEXT ARTICLE
Proteomic Analysis of Serum and Urine of HIV-Monoinfected and HIV/HCV-Coinfected
Patients Undergoing Long Term Treatment with Nevirapine.
Wongtrakul J, Thongtan T, Roytrakul S, et al
Dis Markers.
2014;2014:315824.
Paper
Comparative chromatography-mass spectrometry studies on the antiretroviral
drug nevirapine-Analytical performance characteristics in human plasma
determination.
Sichilongo K, Chinyama M, Massele A, Vento S.
J Chromatogr B Analyt Technol Biomed Life Sci.
2014Jan 15;945-946:101-9
Abstract
Nevirapine Concentrations in Saliva Measured by Thin Layer
Chromatography and Self-Reported Adherence in Patients on Antiretroviral
Therapy at Kilimanjaro Christian Medical Centre, Tanzania.
George L, Muro EP, Ndaro A,
et al
Ther Drug Monit. 2013 Dec 3
Abstract
FULL-TEXT ARTICLE
Simple, precise and accurate HPLC method of analysis for nevirapine suspension
from human plasma.
Halde S, Mungantiwar A, Chintamaneni M
Indian J Pharm Sci.
2011 Jul;73(4):416-21.
Paper |
Use of dried blood spots for the determination of
plasma concentrations of nevirapine and efavirenz.
Kromdijk W, Mulder JW, Rosing H, et al
J Antimicrob Chemother.
2012 Feb 1
Abstract |
Microanalysis of the antiretroviral nevirapine in human hair from
HIV-infected patients by liquid chromatography-tandem
mass spectrometry.
Huang Y, Yang Q, Yoon K,
et
al
Anal Bioanal Chem.
2011 Aug 17
Abstract
Evidence-based Therapeutic Drug Monitoring for
Nevirapine
Muret P, Piedoux S, Solas C, Quaranta S.
Therapie. 2011
May-Jun;66(3):187-95
Abstract
FULL-TEXT ARTICLE
Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase
Inhibitors as a Rapid and Simple
Approach to HIV-1 Drug-Resistance Testing.
Hoffmann D, Garcia AD, Harrigan PR,
et al
PLoS One.
2011;6(7):e22019.
Paper
Usefulness of methadone plasma concentration
measurement in patients receiving nevirapine or efavirenz.
Pelet A, Favrat B, Cavassini M,
Am J Drug Alcohol Abuse.
2011 Jul;37(4):264-8
Abstract
Usefulness of Methadone Plasma Concentration Measurement in Patients
Receiving
Nevirapine
or Efavirenz.
Pelet A, Favrat B, Cavassini M,
et al
Am J Drug Alcohol Abuse.
2011 Jun 23
Abstract
Determination of nevirapine in plasma by GC-MS.
Vogel M, Bertram N, Wasmuth JC,
et al
J Chromatogr Sci.
2010 Feb;48(2):91-4.
Abstract |
Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated
Applications
of NMR and Mass Spectrometries.
Srivastava A, Lian LY, Maggs JL, et al
Drug Metab Dispos.
2009 Oct 1.
Abstract |
|
|
|
|
General Reports
| |
Efavirenz or nevirapine in three-drug combination
therapy with two nucleoside or nucleotide-reverse
transcriptase inhibitors for initial treatment of HIV
infection in antiretroviral-naïve individuals.
Mbuagbaw L, Mursleen S, Irlam JH,
et al
Cochrane Database Syst Rev.
2016 Dec 10;12:CD004246
Paper
Finding of nevirapine extended release tablet remnants in stools does not
threaten the success of combination antiretroviral therapy
Stephan C, León W.
HIV Med. 2013 Sep 23.
Abstract
Long-term clinical and immunologic outcomes of HIV-infected women with and
without previous exposure to nevirapine.
Mudiope PK, Kim S, Wabwire D,
et al
Trop Med Int Health. 2013
Jan 4.
Abstract
Long-term durability of nevirapine-based ART in a cohort of 82 patients after
induction with protease inhibitor treatment.
Rump J, Hoehl J, Rosenberg C.
J Int AIDS Soc. 2012 Nov
11;15(6):18247.
Abstract
Contemporary Role of Nevirapine in HIV Treatment.
Coster LO, Kumar PN.
AIDS Rev. 2012 Apr;14(2):132-44.
Abstract
FULL-TEXT PDF ARTICLE
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in
HIV-infected
patients with or without viral hepatitis B or C infection in Cameroon.
Tchatchueng Mbougua JB, Laurent C, et al
BMC Public Health.
2010 Mar 1;10(1):105
Paper |
Suboptimal Etravirine Activity is Common During Failure of Nevirapine-based
Combination
Antiretroviral Therapy in a Cohort Infected with non-B subtype HIV-1.
Taiwo B, Chaplin B, Penugonda S, et al
Curr HIV Res. 2010 Feb 18.
Abstract |
Safety and efficacy of once-daily nevirapine dosing: a
multicohort study.
Calmy A, Vallier N,
Nguyen A, Lange JM, et al
Antivir Ther.
2009;14(7):931-938.
Abstract |
Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected
Patients After a Median Time of 6
Years on Nevirapine.
Rodríguez-Arrondo F,
Aguirrebengoa K, et al
Curr HIV Res. 2009
Sep;7(5):526-532
Abstract |
Long-term follow-up of nevirapine-treated patients in a
single-centre cohort.
Colafigli M, Di Giambenedetto S, Bracciale L, et al
HIV Med. 2009 May 6.
Abstract |
Plasma Nevirapine Levels and 24-Week Efficacy in HIV-Infected Patients Receiving
Nevirapine-Based
Highly Active Antiretroviral Therapy with or without Rifampicin.
Manosuthi W, Sungkanuparph S, Thakkinstian A, et al
Clin Infect Dis. 2006 Jul 15;43(2):253-5
Abstract
|
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy
and safety
of nevirapine or
efavirenz-based first-line HAART.
van Leth F, Andrews S, Grinsztejn B, Wilkins E
AIDS. 2005 Mar 25;19(5):463-471
Abstract
|
|
NVP vs
ATV
NVP vs EFV
|
|
General
Reports
Drug/Drug
Interactions
